Patients in Romania wait on average 460 days to receive compensated innovative medicines

Mihaela Măncilă

A comprehensive analysis conducted by public health experts at Novartis Romania reveals that Romanian patients may wait, on average, 460 days to access the innovative medicines they need, even after these therapies have been approved for reimbursement by the National Agency for Medicines and Medical Devices (ANMDM). This is one of the key findings of the study titled „Delayed Access to Innovative Medicines in Romania: A Comprehensive Analysis of the Reimbursement Processes”, carried out by a

din zilele anterioare